Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin and Furosemide for Prevention of OHSS in ICSI Cycles
NCT07568886Completed
- Sponsor
- Al-Nahrain University
- Start
- Apr 2019
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of albumin (human) and furosemide in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Al-Nahrain University. Primary endpoints: Incidence of Ovarian Hyperstimulation Syndrome at 14 days and Incidence of Moderate and Severe Ovarian Hyperstimulation Syndrome at 14 days. Started Apr 2019; status: completed.
02
Drugs
albumin (human)furosemide
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT07568886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568886.